| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7709517 | ASTELLAS | Diarylhydantoin compounds |
Aug, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9126941 | ASTELLAS | Treatment of hyperproliferative disorders with diarylhydantoin compounds |
May, 2026
(2 years from now) | |
| US8183274 | ASTELLAS | Treatment of hyperproliferative disorders with diarylhydantoin compounds |
Aug, 2026
(2 years from now) | |
| US11839689 | ASTELLAS | Formulations of enzalutamide |
Sep, 2033
(9 years from now) | |
Xtandi is owned by Astellas.
Xtandi contains Enzalutamide.
Xtandi has a total of 4 drug patents out of which 0 drug patents have expired.
Xtandi was authorised for market use on 04 August, 2020.
Xtandi is available in tablet;oral dosage forms.
Xtandi can be used as treatment of patients with non-metastatic castration-sensitive prostate cancer (nmcspc) with biochemical recurrence (bcr) at high risk for metastasis.
The generics of Xtandi are possible to be released after 11 September, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-926) | Nov 17, 2026 |
| New Indication(I-808) | Dec 16, 2022 |
| New Indication(I-786) | Jul 13, 2021 |
Drugs and Companies using ENZALUTAMIDE ingredient
Market Authorisation Date: 04 August, 2020
Treatment: Treatment of patients with non-metastatic castration-sensitive prostate cancer (nmcspc) with biochemical recurrence (bcr) at high risk for metastasis
Dosage: TABLET;ORAL
XTANDI family patents
